<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="127623">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01742975</url>
  </required_header>
  <id_info>
    <org_study_id>RCB ID: 2011-A01014-37</org_study_id>
    <nct_id>NCT01742975</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Ifabond in Breast Cancer Surgery</brief_title>
  <acronym>Ifabond</acronym>
  <official_title>A Randomized Study Evaluating the Efficacy of the Synthetic Adhesive Solution Ifabond, in Reducing Seroma Formation Post Surgery in Breast Cancer Patients, When Used in Partial Mastectomy With or Without Axillary Lymph Node Dissection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hôpital Européen Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>IfaMEDICAL</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hôpital Européen Marseille</source>
  <oversight_info>
    <authority>France: ANSM (Agence nationale de sécurité du médicament et des produits de santé)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized prospective simple-blind interventional study evaluating the efficacy of the
      synthetic adhesive solution &quot;Ifabond&quot;, in patients undergoing breast cancer surgery. The
      main objective of this study is to determine if the application of Ifabond, in addition to
      the conventional method of breast surgery, reduces the postoperative seroma formation. The
      secondary objective is to assess quality of life immediately after surgery, and the need for
      needle aspiration of the axilla, when using Ifabond.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Breast cancer patients will be selected at their preoperative visit with the surgeon, who
      will inform them about the study and answer their questions.

      Patients who consent to participate will be randomized to one of two arms:

        1. Arm A: Applying Ifabond

        2. Arm B: Without Ifabond

      Patients will be stratified according to these two criteria:

        1. Axillary Lymph Node Dissection planned (ALND)

        2. Body Mass Index (BMI)

      The following parameters will be measured:

        -  ECOG status and Blood Pressure at day 3(day 7 in case of ALND), day 15 and day 30 post
           surgery

        -  Volume of drainage at day 3 and at (day 7 in case of ALND)post surgery

        -  Discomfort alleged by the patient at day 3(day 7 in case of ALND), day 15 and day 30
           post surgery

        -  Lymphocele volume measured by ultrasound at day 15 and day 30 post surgery

        -  If the volume is ≥ 100cc, a needle aspiration will be performed, and the volume of
           aspirate will be documented.

        -  Adverse events and concomitant medications will be collected throughout the study until
           30 days after the last ultrasound.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>Change in seroma formation</measure>
    <time_frame>Day 3 (or 7 in case of axillary lymph node dissection), day15 and day 30 post surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>The volume of drain at Day 3 (or 7 in case of axillary lymph node dissection) post surgery will be documented, then patients will have an ultrasound exam at day 15 and day 30 (+or- 2 days) to measure seroma.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in discomfort alleged by the patient</measure>
    <time_frame>day 3 (or 7), day 15 and day 30</time_frame>
    <safety_issue>No</safety_issue>
    <description>Patients will be asked if they feel any discomfort in relation to seroma formation at Day 3 (or 7 in case of axillary lymph node dissection),day15 and day 30 (-or- 2 days) post surgery.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in the number of needle aspiration required</measure>
    <time_frame>day 15 and day 30</time_frame>
    <safety_issue>No</safety_issue>
    <description>The number of needle aspiration required at day 15 and day30 (-or- 2 days)  post surgery will be documented.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Lymphocele</condition>
  <arm_group>
    <arm_group_label>Arm A: Applying Ifabond</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The synthetic adhesive solution Ifabond, will be applied at the end of conventional breast cancer surgery for arm A patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: without Ifabond</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The synthetic adhesive solution Ifabond, will not be applied at the end of conventional breast cancer surgery in arm B patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>IFABOND (TM)</intervention_name>
    <description>The synthetic adhesive solution Ifabond, will be applied at the end of conventional breast cancer surgery for arm A patients</description>
    <arm_group_label>Arm A: Applying Ifabond</arm_group_label>
    <other_name>An authorized device with CE labeling.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &quot;Eastern Cooperative Oncology Group&quot; ECOG status ≤ 2

          -  Diagnosis of invasive or In situ breast cancer

          -  Patient undergoing partial mastectomy with or without axillary lymph node
             dissection,(without communication between the two surgical loges)

        Exclusion Criteria:

          -  Pregnant or breast-feeding patient

          -  Participation at another protocol with an Investigational drug (within the last 4
             weeks before enrollment)

          -  Known hypersensitivity to Cyanoacrylate

          -  Known hypersensitivity to formaldehyde

          -  Patient who experience systemic infections preoperatively, or have conditions that
             are known to interfere with the healing process

          -  Patient with uncontrolled diabetes
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michel CONTE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Ambroise Paré, Marseille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wahiba BIDAUT, senior CRA</last_name>
    <phone>(33)4-91-83-38-38</phone>
    <phone_ext>3155</phone_ext>
    <email>w_bidaut@ch-ambroisepare.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Penda SOW, CRA</last_name>
    <phone>(33)4-91-83-38-38</phone>
    <phone_ext>3105</phone_ext>
    <email>mp_sow@ch-ambroisepare.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Ambroise Paré</name>
      <address>
        <city>Marseille</city>
        <state>Paca</state>
        <zip>13006</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wahiba BIDAUT, senior CRA</last_name>
      <phone>(33)4-91-83-38-38</phone>
      <phone_ext>3155</phone_ext>
      <email>w_bidaut@ch-ambroisepare.fr</email>
    </contact>
    <contact_backup>
      <last_name>Penda SOW, CRA</last_name>
      <phone>(33)4-91-83-38-38</phone>
      <phone_ext>3105</phone_ext>
      <email>mp_sow@ch-ambroisepare.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Michel CONTE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bernard BLANC, MD/prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Didier MATHIEU, MD/prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean QUILICHINI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre de Chirurgie Gynecologique Et Des Maladies Du Sein</name>
      <address>
        <city>Grenoble</city>
        <state>Rhône-Alpes</state>
        <zip>38000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Raoul PAYAN, MD</last_name>
      <phone>04-76-42-98-01</phone>
      <email>raoul.payan@hotmail.fr</email>
    </contact>
    <investigator>
      <last_name>Raoul PAYAN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <lastchanged_date>December 5, 2012</lastchanged_date>
  <firstreceived_date>December 3, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hôpital Ambroise Paré</investigator_affiliation>
    <investigator_full_name>Michel Conte, M.D.</investigator_full_name>
    <investigator_title>Michel CONTE, obstetrician gynecologist surgeon</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Lymphocele</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
